Search

Displaying results 1281 - 1290 of 10000 in total
  1. Target

    Ectonucleotide pyrophosphatase/phosphodiesterase family member 1

    go.drugbank.com/bio_entities/BE0000457
    TargetHumans

    Preferentially hydrolyzes ATP, but can also hydrolyze other nucleoside 5' triphosphates such as GTP, CTP and UTP to their corresponding monophosphates with release of pyrophosphate, as well as diadenosine … Also able to hydrolyze 2',3'-cGAMP (cyclic GMP-AMP), a second messenger that activates TMEM173/STING and triggers type-I interferon production (PubMed:25344812). 2',3'-cGAMP degradation takes place in

    Synonyms: Alkaline phosphodiesterase I, Phosphodiesterase I/nucleotide pyrophosphatase 1
  2. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    [L40684] The nasal spray formulation of nalmefene was approved by the FDA in May 2023.[L46511] … It is used for complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.

    Categories: Drugs Used in Alcohol Dependence, Drugs Used in Addictive DisordersSynonyms: MORPHINAN-3,14-DIOL, 17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-6-METHYLENE-, (5.ALPHA.)-, 17-(Cyclopropylmethyl)-4,5α-epoxy-6-methylenemorphinan-3,14-diol
  3. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic IndexProducts: TAFINLAR®75 MG CÁPSULAS DURAS, TAFINLAR® 50 MG CÁPSULAS DURAS
  4. Drug

    Segesterone acetate

    go.drugbank.com/drugs/DB14583
    Approved

    Segesterone acetate is not an orally active compound, but it is proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel [A37090]. … On August 10, 2018, Annovera™ containing segesterone acetate and [ethinyl estradiol] was granted approval by the U.S.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 16-Methylene-17-alpha-acetoxy-19-nor-4-pregnene-3,20-dione, 17-Hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione acetate
  5. Drug

    Tocofersolan

    go.drugbank.com/drugs/DB11635
    Approved

    Cholestasis is the reduction or stoppage of bile flow, either to impaired secretion by _hepatocytes_ (liver cells) or obstruction [L2374], [L2375]. … It was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop.

    Mixtures: Eye Health Areds 2 FormulaCategories: Compounds used in a research, industrial, or household setting, Vitamin E
  6. Drug

    Dexamethasone

    go.drugbank.com/drugs/DB01234
    ApprovedInvestigationalVet approved

    Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318] … Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic

    Mixtures: TQ OFTAMOX D UD®, TQ OFTAMOX® D UDCategories: Corticosteroids, Moderately Potent (Group II), P-glycoprotein inducers
  7. Drug

    Relmacabtagene autoleucel

    go.drugbank.com/drugs/DB18979
    Investigational

    Synonyms: (CAR) CONSISTING OF THE HUMAN CD19-SPECIFIC SCFV, AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) TRANSDUCED WITH A NONREPLICATIVE SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR
  8. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment … Telisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  9. Drug

    Lamotrigine

    go.drugbank.com/drugs/DB00555
    ApprovedInvestigational

    Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. … [A191350] Lamotrigine has relatively few side-effects and does not require laboratory monitoring.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
  10. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid … This approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887]

    Synonyms: Rh g-csf fc fusion protein f-627, Recombinant dimeric g-csf fusion protein f627